We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+4.86%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$8.07B
AUM Growth
+$160M
Cap. Flow
-$9.82B
Cap. Flow %
-121.72%
Top 10 Hldgs %
33.87%
Holding
157
New
25
Increased
29
Reduced
33
Closed
16

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$192M
2
ARMO
ARMO BioSciences, Inc. Common Stock
ARMO
+$173M
3
MRK icon
Merck
MRK
+$94.1M
4
THC icon
Tenet Healthcare
THC
+$83.4M
5
DVA icon
DaVita
DVA
+$79.5M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$9.91B
2
LLY icon
Eli Lilly
LLY
+$193M
3
AMGN icon
Amgen
AMGN
+$156M
4
CI icon
Cigna
CI
+$151M
5
ELV icon
Elevance Health
ELV
+$148M

Sector Composition

Rank Sector Weight
1 Healthcare 98%
2 Miscellaneous 1.49%
3 Financials 0.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CELG
151
CALL
DELISTED
Celgene Corp
CELG
– –
-150,000
Closed -$15.7M
3 4 5 6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q1 2018 Portfolio in Review

As of Q1 2018, OrbiMed held 157 positions worth $8.07B, up 2% from $7.91B the previous quarter. Its ten largest holdings account for 34% of the portfolio.

OrbiMed withdrew a net $9.82B in Q1 2018, closing 16 positions and reducing 33 holdings. Its most notable exit was Eli Lilly, an estimated $193M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 97% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, OrbiMed opened a new position in ARMO BioSciences, Inc. Common Stock worth $154M.

  • OrbiMed's largest Q1 2018 buy was ARMO BioSciences, Inc. Common Stock: 4,118,903 shares worth $154M.
  • OrbiMed added most to Bristol-Myers Squibb in Q1 2018, an estimated $192M increase.
  • OrbiMed's biggest Q1 2018 reduction was Loxo Oncology, Inc, cutting an estimated $9.91B.
  • OrbiMed fully exited Eli Lilly in Q1 2018, selling an estimated $193M.
  • OrbiMed's ten largest holdings make up 34% of its $8.07B portfolio in Q1 2018.
  • OrbiMed opened 25 new positions and closed 16 in Q1 2018.
  • OrbiMed's portfolio value rose 2% quarter-over-quarter to $8.07B.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.